JP2003534384A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003534384A5 JP2003534384A5 JP2001587795A JP2001587795A JP2003534384A5 JP 2003534384 A5 JP2003534384 A5 JP 2003534384A5 JP 2001587795 A JP2001587795 A JP 2001587795A JP 2001587795 A JP2001587795 A JP 2001587795A JP 2003534384 A5 JP2003534384 A5 JP 2003534384A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- antagonist
- agonist
- peptide
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 26
- 238000009472 formulation Methods 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 239000000556 agonist Substances 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 239000005557 antagonist Substances 0.000 description 15
- 239000002253 acid Substances 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- 150000008575 L-amino acids Chemical class 0.000 description 9
- 239000000539 dimer Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 239000000178 monomer Substances 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 3
- 102000036693 Thrombopoietin Human genes 0.000 description 3
- 108010041111 Thrombopoietin Proteins 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- LMYNKFDVIZBWDF-UHFFFAOYSA-N 2-azaniumyl-4-bromobutanoate Chemical compound OC(=O)C(N)CCBr LMYNKFDVIZBWDF-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical class C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- 102100036509 Erythropoietin receptor Human genes 0.000 description 1
- 101710102442 Erythropoietin receptor Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- -1 amine imide Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000492 insulin antagonist Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20765400P | 2000-05-26 | 2000-05-26 | |
| US60/207,654 | 2000-05-26 | ||
| PCT/US2001/016654 WO2001091780A1 (en) | 2000-05-26 | 2001-05-23 | Neuroprotective peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003534384A JP2003534384A (ja) | 2003-11-18 |
| JP2003534384A5 true JP2003534384A5 (enExample) | 2008-07-03 |
Family
ID=22771463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001587795A Pending JP2003534384A (ja) | 2000-05-26 | 2001-05-23 | 神経保護性ペプチド |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1296702A4 (enExample) |
| JP (1) | JP2003534384A (enExample) |
| CN (1) | CN1318084C (enExample) |
| AU (2) | AU7490401A (enExample) |
| BR (1) | BR0111182A (enExample) |
| CA (1) | CA2410453A1 (enExample) |
| IL (1) | IL153079A0 (enExample) |
| MX (1) | MXPA02011727A (enExample) |
| NZ (1) | NZ522924A (enExample) |
| WO (1) | WO2001091780A1 (enExample) |
| ZA (1) | ZA200210304B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE296350T1 (de) | 1999-06-14 | 2005-06-15 | Genentech Inc | Strukturiertes peptidgerüst zur ausstellung von drehung-bibliotheken auf phage |
| US20030166003A1 (en) * | 1999-06-14 | 2003-09-04 | Cochran Andrea G. | Structured peptide scaffold for displaying turn libraries on phage |
| US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| US6914123B2 (en) | 2001-04-17 | 2005-07-05 | Genentech, Inc. | Hairpin peptides with a novel structural motif and methods relating thereto |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| DE602004031390D1 (de) | 2003-05-06 | 2011-03-24 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten |
| EP1625156B1 (en) * | 2003-05-12 | 2012-09-19 | Affymax, Inc. | Peptides that bind to the erythropoietin receptor |
| EP1626983B8 (en) | 2003-05-12 | 2010-12-22 | Affymax, Inc. | Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof |
| AU2004238870B8 (en) | 2003-05-12 | 2010-04-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| JP2007500218A (ja) | 2003-05-12 | 2007-01-11 | アフィーマックス・インコーポレイテッド | ポリ（エチレングリコール）修飾ペプチド系化合物の新規スペーサー部分 |
| US7589063B2 (en) | 2004-12-14 | 2009-09-15 | Aplagen Gmbh | Molecules which promote hematopoiesis |
| EP1848461A2 (en) | 2005-02-16 | 2007-10-31 | Nektar Therapeutics Al, Corporation | Conjugates of an epo moiety and a polymer |
| US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| EP1857463A1 (en) * | 2006-05-03 | 2007-11-21 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Peptide having neuroprotective effects |
| EP2275142A3 (en) | 2006-06-30 | 2011-05-11 | Andre Koltermann | Conjugates for immunotherapy of cancer |
| EP2118127A4 (en) | 2007-01-31 | 2010-12-01 | Affymax Inc | NICKET-BASED LINKER FOR BONDING MODIFYING GROUPS OF POLYPEPTIDES AND OTHER MACROMOLECULES |
| EP2018835B1 (de) | 2007-07-09 | 2014-03-05 | Augustinus Bader | Wirkstoff abgebendes Pflaster |
| SG10201604530SA (en) * | 2008-01-22 | 2016-07-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| US8426402B2 (en) | 2009-02-05 | 2013-04-23 | Immunogen, Inc. | Benzodiazepine derivatives |
| RU2410392C2 (ru) | 2009-02-16 | 2011-01-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН | Дипептидные миметики нейротрофинов ngf и bdnf |
| WO2012003960A1 (en) | 2010-07-06 | 2012-01-12 | Augustinus Bader | Topical application of erythropoietin for the treatment of eye disorders and injuries |
| IL279304B (en) * | 2011-02-15 | 2022-07-01 | Immunogen Inc | Method for producing an indolinobenzodiazepine |
| KR20160052537A (ko) * | 2013-07-17 | 2016-05-12 | 아라임 파마슈티칼즈, 인크. | 조직 손상과 연관된 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 |
| CN105017406B (zh) * | 2014-04-21 | 2020-10-09 | 上海市第一人民医院 | 一类新的具有神经保护功能的多肽 |
| CN105233256A (zh) * | 2015-10-28 | 2016-01-13 | 中国人民解放军第三军医大学 | 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用 |
| GB201609083D0 (en) | 2016-05-24 | 2016-07-06 | Syntab Therapeutics Gmbh | Synthetic compound |
| TW202024117A (zh) | 2018-09-14 | 2020-07-01 | 日商Ｅｐｏ醫藥股份有限公司 | 抗紅血球生成素受體胜肽 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
| US6165783A (en) * | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
-
2001
- 2001-05-23 IL IL15307901A patent/IL153079A0/xx unknown
- 2001-05-23 NZ NZ52292401A patent/NZ522924A/xx not_active IP Right Cessation
- 2001-05-23 BR BR0111182-5A patent/BR0111182A/pt not_active Application Discontinuation
- 2001-05-23 MX MXPA02011727A patent/MXPA02011727A/es unknown
- 2001-05-23 AU AU7490401A patent/AU7490401A/xx active Pending
- 2001-05-23 AU AU2001274904A patent/AU2001274904B2/en not_active Ceased
- 2001-05-23 WO PCT/US2001/016654 patent/WO2001091780A1/en not_active Ceased
- 2001-05-23 JP JP2001587795A patent/JP2003534384A/ja active Pending
- 2001-05-23 EP EP01941562A patent/EP1296702A4/en not_active Withdrawn
- 2001-05-23 CN CNB018131794A patent/CN1318084C/zh not_active Expired - Fee Related
- 2001-05-23 CA CA002410453A patent/CA2410453A1/en not_active Abandoned
-
2002
- 2002-12-19 ZA ZA200210304A patent/ZA200210304B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003534384A5 (enExample) | ||
| US8633153B2 (en) | Transthyretin variants | |
| Pasut et al. | PEGylation of proteins as tailored chemistry for optimized bioconjugates | |
| ES2280083T3 (es) | Composiciones de proteinas de fusion ob y metodos. | |
| TWI250988B (en) | Thrombopoietic compounds | |
| US7030218B2 (en) | Pseudo native chemical ligation | |
| TW570802B (en) | Improved interferon polymer conjugates | |
| JP4157277B2 (ja) | 実質的に純粋なヒスチジン結合タンパク質−ポリマー結合体 | |
| JP2018058884A (ja) | 組換えエリスロポエチンと部分的に組合されたｉｌ−１インヒビターおよびｔｎｆアンタゴニストの貧血治療用途 | |
| KR20060023123A (ko) | 폴리(에틸렌 글리콜)-개질된 펩티드 기재 화합물용 신규간격자 부분 | |
| JP2005509609A5 (enExample) | ||
| CA2525464A1 (en) | Novel poly(ethylene glycol) modified compounds and uses thereof | |
| RS51852B (sr) | Modifikovani peptidi kao terapeutski agensi | |
| KR20060135887A (ko) | 신규의 ｇ-ｃｓｆ 콘쥬게이트 | |
| US8906355B2 (en) | Synthetic stereoisomer peptides in the retro-inverso and inverso configuration, and with cyclic and linear structure, their polymer conjugates, their encapsulation in polymer particles, and uses thereof | |
| CN102421447A (zh) | 用peg标记干扰素的方法 | |
| ES2241040T3 (es) | Proteinas hibridas que forman heterodimeros. | |
| KR100507796B1 (ko) | 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법 | |
| IL273368B2 (en) | Composite medical preparations with increased binding capacity to albumin | |
| TW201138831A (en) | Modified granulocyte colony stimulating factor (G-CSF) | |
| ES2360203T3 (es) | Ligación química "seudo"- natural. | |
| KR100459105B1 (ko) | 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체 | |
| ZA200505707B (en) | Polymer conjugates of mutated neublastin | |
| LT6164B (lt) | Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas | |
| CN102724980B (zh) | 蛋白-聚合物偶联物的治疗用途 |